Cell Medica has a robust pipeline of cellular immunotherapy products.
In the field of engineered TCRs, we are working with University College London, to develop the Dominant TCR technology to improve the potency of TCR-modified T cells while maintaining the safety profile.
Our product portfolio also includes baltaleucel-T (CMD-003, Virus Specific T cells) for the treatment of lymphomas associated with the Epstein Barr virus.
Our dominant T cell receptor (dTCR) technology is currently in development and is a genetic approach to optimizing the function of TCRs.
The genes of the TCRs are isolated and modified before being introduced to T cells that would otherwise struggle to respond to the cancer or that lack a TCR capable of recognizing the cancer antigen.
CMD-003 consists of patient-derived (autologous) Epstein-Barr virus (EBV)-specific T cells. The T cells specifically target four EBV epitopes (LMP1, LMP2, EBNA1 and BARF1).
EBV infects more than 90% of the human population on a latent basis and is connected to a variety of cancers. CMD-003 has potential for the treatment of patients with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) as well as nasopharyngeal carcinoma (NPC) and post-transplant lymphoproliferative disease (PTLD).
Cell Medica presented encouraging results of Phase II CITADEL trial with EBV specific T-cell product, baltaleucel-T (CMD-003), at the 2018 Annual SITC Meeting in Washington DC. (abstract P240, Poster)
We are actively exploring partnering opportunities for our EBV targeted T cell platform. Please see our Partnering page for contact information.